H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 89 Citations 25,463 330 World Ranking 6400 National Ranking 3503

Research.com Recognitions

Awards & Achievements

2009 - Fellow of the American Statistical Association (ASA)

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

The scientist’s investigation covers issues in Internal medicine, Surgery, Oncology, Endocrinology and Gastroenterology. The concepts of his Internal medicine study are interwoven with issues in Diabetes mellitus and Pathology. His studies examine the connections between Surgery and genetics, as well as such issues in Cancer, with regards to Loss of heterozygosity.

His study in the field of Induction chemotherapy is also linked to topics like In patient. The Endocrinology study combines topics in areas such as Maternal hypothyroidism, Birth weight and Inflammatory bowel disease. His research in Gastroenterology intersects with topics in Irinotecan, Neutropenia, Toxicity, Proctocolectomy and Genotype.

His most cited work include:

  • Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. (828 citations)
  • UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity (588 citations)
  • Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. (532 citations)

What are the main themes of his work throughout his whole career to date?

Theodore Karrison focuses on Internal medicine, Oncology, Surgery, Gastroenterology and Cancer research. His research combines Endocrinology and Internal medicine. In Oncology, he works on issues like Cancer, which are connected to Toxicity.

He works on Surgery which deals in particular with Prospective cohort study. His Gastroenterology study combines topics from a wide range of disciplines, such as Irinotecan and Neutropenia. His Irinotecan research integrates issues from Tolerability, Genotype and Dosing.

He most often published in these fields:

  • Internal medicine (48.46%)
  • Oncology (29.69%)
  • Surgery (14.01%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (48.46%)
  • Oncology (29.69%)
  • Gastroenterology (9.50%)

In recent papers he was focusing on the following fields of study:

Internal medicine, Oncology, Gastroenterology, Pembrolizumab and Randomized controlled trial are his primary areas of study. Theodore Karrison applies his multidisciplinary studies on Internal medicine and In patient in his research. The various areas that Theodore Karrison examines in his Oncology study include Androgen deprivation therapy, Prostate cancer, Ipilimumab, Immunotherapy and Radiation therapy.

The study incorporates disciplines such as Oxaliplatin, Anastomosis and Cohort in addition to Gastroenterology. The concepts of his Pembrolizumab study are interwoven with issues in Previously treated and Mesothelioma. He interconnects Tocilizumab, Low dose and Confidence interval in the investigation of issues within Randomized controlled trial.

Between 2017 and 2021, his most popular works were:

  • Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. (219 citations)
  • Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial (74 citations)
  • Optima: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (61 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His primary scientific interests are in Internal medicine, Oncology, Pembrolizumab, Randomized controlled trial and Gastroenterology. His research related to Interquartile range, Clinical endpoint, Lymph node, Androgen deprivation therapy and Salvage radiotherapy might be considered part of Internal medicine. His research integrates issues of Cancer, Human Papillomavirus Positive, Immunotherapy, Disease and De-escalation in his study of Oncology.

His research in Pembrolizumab intersects with topics in Previously treated, Mesothelioma, Biopsy, Melanoma and Ipilimumab. His Randomized controlled trial research is multidisciplinary, incorporating elements of Tocilizumab, Low dose, Phases of clinical research and Premature birth. His study in Gastroenterology is interdisciplinary in nature, drawing from both Irinotecan, Oxaliplatin, Retrospective cohort study, Colon surgery and Cohort.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Federico Innocenti;Samir D. Undevia;Lalitha Iyer;Pei Xian Chen.
Journal of Clinical Oncology (2004)

1072 Citations

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

L Iyer;S Das;L Janisch;M Wen.
Pharmacogenomics Journal (2002)

789 Citations

Critical Evaluation of Diagnostic Aids for the Detection of Oral Cancer

Mark W. Lingen;John R. Kalmar;Theodore Karrison;Paul M. Speight.
Oral Oncology (2008)

746 Citations

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

Sonali M. Smith;Michelle M. Le Beau;Dezheng Huo;Theodore Karrison.
Blood (2003)

689 Citations

Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Hedy L. Kindler;Gregory Friberg;Deepti A. Singh;Gershon Locker.
Journal of Clinical Oncology (2005)

600 Citations

Quantitative study of insulin secretion and clearance in normal and obese subjects.

K S Polonsky;B D Given;L Hirsch;E T Shapiro.
Journal of Clinical Investigation (1988)

572 Citations

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.

D A Ehrmann;J Sturis;M M Byrne;T Karrison.
Journal of Clinical Investigation (1995)

543 Citations

Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997.

Mark Haas;Shane M. Meehan;Theodore G. Karrison;Benjamin H. Spargo.
American Journal of Kidney Diseases (1997)

511 Citations

Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.

K S Polonsky;J Licinio-Paixao;B D Given;W Pugh.
Journal of Clinical Investigation (1986)

506 Citations

Dormancy of Mammary Carcinoma After Mastectomy

Theodore G. Karrison;Donald J. Ferguson;Paul Meier.
Journal of the National Cancer Institute (1999)

502 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Theodore Karrison

Ralph R. Weichselbaum

Ralph R. Weichselbaum

University of Chicago

Publications: 77

Mark J. Ratain

Mark J. Ratain

University of Chicago

Publications: 73

Kenneth S. Polonsky

Kenneth S. Polonsky

University of Chicago

Publications: 59

Everett E. Vokes

Everett E. Vokes

University of Chicago

Publications: 48

Chun-Su Yuan

Chun-Su Yuan

University of Chicago

Publications: 41

Howard L. McLeod

Howard L. McLeod

Central South University

Publications: 38

Ravi Salgia

Ravi Salgia

City Of Hope National Medical Center

Publications: 35

Ezra E.W. Cohen

Ezra E.W. Cohen

University of California, San Diego

Publications: 33

Jitender P. Dubey

Jitender P. Dubey

United States Department of Agriculture

Publications: 32

Walter M. Stadler

Walter M. Stadler

University of Chicago

Publications: 32

Hedy L. Kindler

Hedy L. Kindler

University of Chicago

Publications: 29

Michelle M. Le Beau

Michelle M. Le Beau

University of Chicago

Publications: 27

Jos H. Beijnen

Jos H. Beijnen

Antoni van Leeuwenhoek Hospital

Publications: 26

Alex Sparreboom

Alex Sparreboom

The Ohio State University

Publications: 25

Claudio Cobelli

Claudio Cobelli

University of Padua

Publications: 25

Jose G. Montoya

Jose G. Montoya

Palo Alto Medical Foundation

Publications: 24

Something went wrong. Please try again later.